Abeona Therapeutics

ABEONA THERAPEUTICS INC

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.

New,York,,Usa,-,January,07,,2025:,E2open,Website,Displayed

ABEO

BLMZ

CMBM

DGLY

DGNX

ETWO

GORV

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

IMNN

IXHL

ONCY

PMAX

PRTA

SBET

SILO

VVPR

WORX

Consulta las acciones con mayores subidas y caídas en el premercado estadounidense de hoy, incluyendo tecnológicas, biotecnológicas y más.

Las acciones de E2open se disparan un 25%; aquí están 20 acciones que se mueven en el premercado

Abeona Therapeutics Inc

Health Care

Press Releases

Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy

Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million

Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy

General

ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area

AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients

News

Financing

Earnings

Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates

TECH

ADC Therapeutics

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Amarin Corporation plc - American Depositary Shares

Amarin Corp

Astria Therapeutics

Aura Biosciences

Benitec Biopharma

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

CytomX Therapeutics

Bright Minds Biosciences Inc. - common stock

Bright Minds Biosciences

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

I-MAB

Inhibrx Biosciences

Kamada

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Ocugen

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

ProKidney Corp. - Class A Ordinary Shares

ProKidney

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Replimune Group

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

XOMA Royalty

Y-mAbs Therapeutics

HC Wainwright & Co.

Oppenheimer

Stifel

Comments

Abeona Therapeutics

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL